Research On Business Model Optimization Of TZ Pharmaceutical Company

As one of the national strategic emerging industries,the pharmaceutical industry plays a pivotal role in the overall situation of economic and social development.The "Fourteenth Five Year Plan" period is the key five years for China’s bio pharmaceutical industry to transform into an innovation driven industry and realize the transformation from big to strong.The country has included the development of bio pharmaceutical industry in the "Fourteenth Five Year Plan" national special plan,which shows its importance to future economic growth,social stability and people’s happiness.In recent years,as the living standard of residents increases year by year,people’s awareness of self health is gradually enhanced,and the demand for medical care is also slowly rising.For this reason,the state has successively introduced new medical reform policies such as medical insurance fee control,drug "two ticket system","4+7" drug centralized procurement with quantity to standardize the development of the pharmaceutical industry,and has successively introduced a number of policies to encourage pharmaceutical enterprises to research and develop innovation and break through the technical bottleneck.At the same time,in order to encourage and guide the orderly development of the big health industry,and promote China to accelerate the transition from a big pharmaceutical country to a strong pharmaceutical country,the newly revised Drug Administration Law of the People’s Republic of China was promulgated on December 1,2019,which revised the drug marketing license holder system(i.e.,the "MAH" system),making the drug registration system transform from the "binding system" of marketing license and production license to the "separation system",It has greatly stimulated the enthusiasm of drug research and development,and also driven the development of drug CRO,CMO and other services.Under the above background,it is worth pondering at this stage how to follow the trend and find a business model suitable for its development.TZ Pharmaceutical Co.,Ltd.is a comprehensive modern pharmaceutical group company integrating drug research and development,production,operation and cultivation of Chinese medicinal materials.Faced with the new development environment,the company has gradually exposed problems such as low operating efficiency,poor management efficiency,and difficulty in adapting to the rapidly changing market.Therefore,restructuring its business model has become an inevitable choice.The purpose of this paper is to optimize the business model of TZ Pharmaceutical Company under the new environment,analyze its implementation path,and propose targeted management strategies.The main contents of this paper include:First,analyze the existing business model and characteristics of TZ Pharmaceutical Company,and diagnose the existing problems.Secondly,analyze the development environment of TZ Pharmaceutical Company,and define the business objectives and direction of the enterprise in combination with its resource and capacity endowment.Then,TZ Pharmaceutical Company proposed the business model of "centralized production,diversified operation and platform management" to adapt to the development situation and change trend of modern medicine,and reorganized its business development mode,business process,profit model and management system mechanism.Finally,the implementation path and safeguard measures of TZ Pharmaceutical Company’s business model reform are proposed.The research in this paper has important practical significance for the development of TZ pharmaceutical industry,and also has general reference value for similar enterprises.